Id: acc4966
Group: 1sens
Protein: EGFR
Gene Symbol: EGFR
Protein Id: P00533
Protein Name: EGFR_HUMAN
PTM: sulfenylation
Site: Cys797
Site Sequence: LITQLMPFGCLLDYVREHKDN
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype:
Disease Cellline: H187
Disease Info:
Drug: DUOX1 KO
Drug Info: "DUOX1 KO refers to the knockout of the DUOX1 gene. This genetic manipulation leads to the inactivation of the DUOX1 gene, which may help researchers study the biological functions of DUOX1 and its potential roles in related physiological and pathological processes."
Effect: modulate
Effect Info: "DUOX1 silencing reduces EGFR cysteine sulfonation, a modification that positively regulates EGFR kinase activity. DUOX1 silencing promotes EMT via nuclear EGFR signaling, enhancing the invasion and metastasis capabilities of cancer cells."
Note: Non-conventional drugs
Score: 3.0
Pubmed(PMID): 30890751
Sentence Index:
Sentence:

Sequence & Structure:

MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
EGFR LAPATINIB DITOSYLATE Epidermal growth factor receptor erbB1 inhibitor 4 - breast carcinoma FDA
EGFR NERATINIB MALEATE Epidermal growth factor receptor erbB1 inhibitor 4 - breast carcinoma FDA
EGFR CETUXIMAB Epidermal growth factor receptor erbB1 inhibitor 4 - colorectal adenocarcinoma DailyMed
EGFR PANITUMUMAB Epidermal growth factor receptor erbB1 inhibitor 4 - colorectal adenocarcinoma DailyMed
EGFR NECITUMUMAB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR AMIVANTAMAB Epidermal growth factor receptor inhibitor 4 - neoplasm ATC
EGFR CETUXIMAB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR CETUXIMAB Epidermal growth factor receptor erbB1 inhibitor 4 Recruiting neoplasm ClinicalTrials
EGFR VANDETANIB Epidermal growth factor receptor inhibitor 4 - neoplasm ATC
EGFR PANITUMUMAB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR GEFITINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR DACOMITINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR MOBOCERTINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR OSIMERTINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR BRIGATINIB Epidermal growth factor receptor erbB1 inhibitor 4 - neoplasm ATC
EGFR CETUXIMAB Epidermal growth factor receptor erbB1 inhibitor 4 - squamous cell carcinoma DailyMed
EGFR VANDETANIB Epidermal growth factor receptor inhibitor 4 - thyroid carcinoma DailyMed
EGFR NECITUMUMAB Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma EMA
DailyMed
EGFR AFATINIB DIMALEATE Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma DailyMed
EGFR AFATINIB DIMALEATE Epidermal growth factor receptor erbB1 inhibitor 4 Not yet recruiting non-small cell lung carcinoma ClinicalTrials
EGFR DACOMITINIB Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma FDA
EMA
EGFR OSIMERTINIB MESYLATE Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma EMA
DailyMed
EGFR ERLOTINIB HYDROCHLORIDE Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma DailyMed
EGFR BRIGATINIB Epidermal growth factor receptor erbB1 inhibitor 4 - non-small cell lung carcinoma EMA
FDA
EGFR AMIVANTAMAB Epidermal growth factor receptor inhibitor 4 - non-small cell lung carcinoma EMA
FDA

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
R 1175 A Breast cancer/tumor/carcinoma Methylation 21258366
- - A Renal tubulointerstitial fibrosis Ubiquitination 32017279
- - A Lung adenocarcinoma Phosphorylation 23866081
- - A B-cell chronic lymphocytic leukemia Phosphorylation 23866081
- - D Gastric adenocarcinoma Glycosylation 30323967
- - D Bladder cancer Ubiquitination 33253711
- - D Osteosarcoma Ubiquitination 32775001
- - D Breast cancer Ubiquitination 31801577
- - D Lung adenocarcinoma Ubiquitination 37240137
- - D Cardiac hypertrophy Ubiquitination 32494592
- - D Thyroid cancer/carcinoma Phosphorylation 16822827
Y 1068 D Glioblastoma multiforme Phosphorylation 35915159
Y 1045 D Non-small cell lung cancer/carcinoma Phosphorylation 18687633
S 768 N Non-small cell lung cancer/carcinoma Phosphorylation 17653080
S 768 N Esophageal cancer Phosphorylation 16357520 ;  16357520
T 790 N Non-small cell lung cancer/carcinoma Phosphorylation 18199554
S 768 N Non-small cell lung cancer Phosphorylation 20522446 ;  26870223
S 768 N Esophageal squamous cell carcinoma Phosphorylation 16357520
Y 845 P Lung adenocarcinoma Phosphorylation 23866081
- - P Epidermoid carcinoma Phosphorylation 23499740
Y 992 P Gastric cancer Phosphorylation 23613900
Y 1068 P Gastric cancer Phosphorylation 23613900
Y 1068 P Tonsillar cancer Phosphorylation 23564800
- - P Lung adenocarcinoma Phosphorylation 23866081
- - P Thyroid cancer/carcinoma Phosphorylation 11299771
Y 1148 P Tonsillar cancer Phosphorylation 23564800
- - P B-cell chronic lymphocytic leukemia Phosphorylation 23866081
- - U Head and neck squamous cell carcinoma Phosphorylation 23799848
- - U Colon cancer/carcinoma Phosphorylation 24665413
S 1046 U Non-small cell lung cancer/carcinoma Phosphorylation 23520446
- - U Hepatocellular carcinoma Ubiquitination 32382041
Y 1068 U Pancreatic cancer Phosphorylation 31851779
Y 1172 U Pancreatic cancer Phosphorylation 31851779
- - U Breast cancer Ubiquitination 36841821
T 654 U Breast cancer Phosphorylation 31597954 ;  33958726
- - U Gastric cancer Ubiquitination 34034092
S 1166 U Lung cancer/carcinoma Phosphorylation 22703031
- - U Hepatocellular carcinoma Ubiquitination 33116595
- - U Glioblastoma Ubiquitination 36335869
K 721 U Head and neck squamous cell carcinoma Methylation 28102297
K 689 U Non-small cell lung cancer Ubiquitination 32694521
- - U Follicular thyroid carcinoma Glycosylation 32442537
- - U Head and neck squamous cell carcinoma Glycosylation 29930379
Y 1197 U Squamous cell carcinoma Phosphorylation 37109043
Y 1068 U Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 22307624
Y 845 U Liver cancer Phosphorylation 23220047
Y 922 U Non-small cell lung cancer/carcinoma Phosphorylation 19002495
Y 992 U Glioblastoma multiforme Phosphorylation 17575160
Y 1068 U Squamous cell carcinoma Phosphorylation 37109043
Y 1086 U Breast cancer/tumor/carcinoma Phosphorylation 22222162
Y 1086 U Squamous cell carcinoma Phosphorylation 37109043
Y 1092 U Non-small cell lung cancer/carcinoma Phosphorylation 28724430 ;  17653080
Y 1148 U Non-small cell lung cancer/carcinoma Phosphorylation 18687633
Y 1173 U Non-small cell lung cancer/carcinoma Phosphorylation 19002495
- - U Ovarian cancer/carcinoma Phosphorylation 22952709
Y 869 U Non-small cell lung cancer/carcinoma Phosphorylation 16505275 ;  17653080
Y 845 U Squamous cell carcinoma Phosphorylation 37109043
Y 845 U Non-small cell large cell lung carcinoma Phosphorylation 16505275 ;  16505275
Y 845 U Breast cancer/tumor/carcinoma Phosphorylation 22179831 ;  23066441
Y 845 U Hepatocellular carcinoma Phosphorylation 16936701
Y 845 U Non-small cell squamous cell lung carcinoma Phosphorylation 16505275 ;  16505275
Y 1068 U Non-small cell lung cancer/carcinoma Phosphorylation 22901364 ;  18687633
- - U Non-small cell lung cancer Phosphorylation 36896765
- - U Glioma Phosphorylation 24403856

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: